Journal article
Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease
Science translational medicine, Vol.10(461), p.eaar3959
10/03/2018
DOI: 10.1126/scitranslmed.aar3959
PMID: 30282695
Abstract
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by a mutation in the huntingtin (HTT) protein, resulting in acquisition of toxic functions. Previous studies have shown that lowering mutant HTT has the potential to be broadly beneficial. We previously identified
Details
- Title: Subtitle
- Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease
- Creators
- Amber L Southwell - Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia V5Z 4H4, CanadaHolly B Kordasiewicz - Ionis Pharmaceuticals, Carlsbad, CA 92008, USADouglas Langbehn - Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USANiels H Skotte - Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia V5Z 4H4, CanadaMatthew P Parsons - Department of Psychiatry, Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia V6T 1Z3, CanadaErika B Villanueva - Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia V5Z 4H4, CanadaNicholas S Caron - Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia V5Z 4H4, CanadaMichael E Østergaard - Ionis Pharmaceuticals, Carlsbad, CA 92008, USALisa M Anderson - Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia V5Z 4H4, CanadaYuanyun Xie - Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia V5Z 4H4, CanadaLouisa Dal Cengio - Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia V5Z 4H4, CanadaHailey Findlay-Black - Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia V5Z 4H4, CanadaCrystal N Doty - Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia V5Z 4H4, CanadaBethany Fitsimmons - Ionis Pharmaceuticals, Carlsbad, CA 92008, USAEric E Swayze - Ionis Pharmaceuticals, Carlsbad, CA 92008, USAPunit P Seth - Ionis Pharmaceuticals, Carlsbad, CA 92008, USALynn A Raymond - Department of Psychiatry, Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia V6T 1Z3, CanadaC Frank Bennett - Ionis Pharmaceuticals, Carlsbad, CA 92008, USAMichael R Hayden - Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia V5Z 4H4, Canada. mrh@cmmt.ubc.ca
- Resource Type
- Journal article
- Publication Details
- Science translational medicine, Vol.10(461), p.eaar3959
- DOI
- 10.1126/scitranslmed.aar3959
- PMID
- 30282695
- NLM abbreviation
- Sci Transl Med
- ISSN
- 1946-6242
- eISSN
- 1946-6242
- Publisher
- United States
- Grant note
- DOI: 10.13039/100009836, name: Huntington Society of Canada; DOI: 10.13039/501100000024, name: Canadian Institutes of Health Research, award: MOP-84438; DOI: 10.13039/100013669, name: IONIS Pharmaceuticals
- Language
- English
- Date published
- 10/03/2018
- Academic Unit
- Psychiatry; Iowa Neuroscience Institute
- Record Identifier
- 9984004000002771
Metrics
44 Record Views